S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
MarketBeat Week in Review – 6/4 - 6/9
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
How major US stock indexes fared Friday 6/9/2023
FuelCell Is Back To Realistic Valuation
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
New Mexico reaches $500M settlement with Walgreens in opioid case
Nigeria's central bank chief arrested after being suspended by president
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
American Airlines, JetBlue seek to keep some ties despite losing antitrust case
Oregon Democratic Party to send federal officials a $500,000 donation from former FTX executive
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
MarketBeat Week in Review – 6/4 - 6/9
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
How major US stock indexes fared Friday 6/9/2023
FuelCell Is Back To Realistic Valuation
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
New Mexico reaches $500M settlement with Walgreens in opioid case
Nigeria's central bank chief arrested after being suspended by president
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
American Airlines, JetBlue seek to keep some ties despite losing antitrust case
Oregon Democratic Party to send federal officials a $500,000 donation from former FTX executive
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
MarketBeat Week in Review – 6/4 - 6/9
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
How major US stock indexes fared Friday 6/9/2023
FuelCell Is Back To Realistic Valuation
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
New Mexico reaches $500M settlement with Walgreens in opioid case
Nigeria's central bank chief arrested after being suspended by president
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
American Airlines, JetBlue seek to keep some ties despite losing antitrust case
Oregon Democratic Party to send federal officials a $500,000 donation from former FTX executive
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
MarketBeat Week in Review – 6/4 - 6/9
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
How major US stock indexes fared Friday 6/9/2023
FuelCell Is Back To Realistic Valuation
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
New Mexico reaches $500M settlement with Walgreens in opioid case
Nigeria's central bank chief arrested after being suspended by president
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
American Airlines, JetBlue seek to keep some ties despite losing antitrust case
Oregon Democratic Party to send federal officials a $500,000 donation from former FTX executive

Royalty Pharma (RPRX) Stock Forecast, Price & News

$32.91
-1.62 (-4.69%)
(As of 06/9/2023 ET)
Compare
Today's Range
$32.82
$33.96
50-Day Range
$32.22
$36.56
52-Week Range
$32.02
$44.66
Volume
3.39 million shs
Average Volume
2.31 million shs
Market Capitalization
$19.98 billion
P/E Ratio
59.84
Dividend Yield
2.43%
Price Target
$54.00

Royalty Pharma MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
64.1% Upside
$54.00 Price Target
Short Interest
Healthy
1.92% of Float Sold Short
Dividend Strength
Weak
Based on Four Factors
Sustainability
-2.25
Upright™ Environmental Score
News Sentiment
0.36mentions of Royalty Pharma in the last 14 days
Based on 12 Articles This Week
Insider Trading
Selling Shares
$65.31 M Sold Last Quarter
Proj. Earnings Growth
-5.30%
From $4.15 to $3.93 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

3.30 out of 5 stars

Finance Sector

23rd out of 837 stocks

Pharmaceutical Preparations Industry

2nd out of 482 stocks


RPRX stock logo

About Royalty Pharma (NASDAQ:RPRX) Stock

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

Receive RPRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Royalty Pharma and its competitors with MarketBeat's FREE daily newsletter.

RPRX Stock News Headlines

Sell Every Stock, Except ONE (Ticker Revealed)
We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.
Sell Every Stock, Except ONE (Ticker Revealed)
We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.
CEO of Royalty Pharma Makes $4.84M Buy
Royalty Pharma Reports First Quarter 2023 Results
See More Headlines

RPRX Price History

RPRX Company Calendar

Last Earnings
11/10/2021
Ex-Dividend for 3/15 Dividend
2/15/2023
Dividend Payable
3/15/2023
Ex-Dividend for 6/15 Dividend
5/18/2023
Today
6/10/2023
Dividend Payable
6/15/2023
Next Earnings (Estimated)
8/03/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Finance
Current Symbol
NASDAQ:RPRX
CUSIP
76028H20
Fax
N/A
Employees
51
Year Founded
1996

Price Target and Rating

Average Stock Price Forecast
$54.00
High Stock Price Forecast
$60.00
Low Stock Price Forecast
$48.00
Forecasted Upside/Downside
+64.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$42.83 million
Pretax Margin
25.90%

Debt

Sales & Book Value

Annual Sales
$2.24 billion
Cash Flow
$3.55 per share
Book Value
$15.69 per share

Miscellaneous

Free Float
456,203,000
Market Cap
$19.98 billion
Optionable
Not Optionable
Beta
0.42

Social Links


Key Executives

  • Mr. Pablo Gerardo Legorreta (Age 59)
    Founder, Chairman & CEO
  • Mr. Terrance P. Coyne
    Exec. VP & CFO
  • Mr. George Wingate Lloyd (Age 64)
    Exec. VP of Investments & Chief Legal Officer
    Comp: $4.35M
  • Mr. Christopher Hite (Age 56)
    Vice Chairman & Exec. VP
    Comp: $4.35M
  • Dr. Marshall Urist M.D.
    Ph.D., Exec. VP and Head of Research & Investments
  • Mr. Arthur R. McGivern J.D.
    Exec. VP of Investments & Gen. Counsel
  • Mr. Ashwin Pai M.D.
    Exec. VP of Investments
  • Ms. Kristin Stafford (Age 41)
    Sr. VP & Chief Accounting Officer
  • Dr. James Folmar Reddoch Ph.D. (Age 53)
    Exec. VP of Investments & Chief Scientific Officer
  • Mr. George Grofik C.F.A.
    CPA, Sr. VP and Head of Investor Relations & Communications













RPRX Stock - Frequently Asked Questions

Should I buy or sell Royalty Pharma stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Royalty Pharma in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" RPRX shares.
View RPRX analyst ratings
or view top-rated stocks.

What is Royalty Pharma's stock price forecast for 2023?

4 Wall Street analysts have issued 1 year price objectives for Royalty Pharma's stock. Their RPRX share price forecasts range from $48.00 to $60.00. On average, they anticipate the company's share price to reach $54.00 in the next twelve months. This suggests a possible upside of 64.1% from the stock's current price.
View analysts price targets for RPRX
or view top-rated stocks among Wall Street analysts.

How have RPRX shares performed in 2023?

Royalty Pharma's stock was trading at $39.52 at the beginning of the year. Since then, RPRX stock has decreased by 16.7% and is now trading at $32.91.
View the best growth stocks for 2023 here
.

When is Royalty Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our RPRX earnings forecast
.

How were Royalty Pharma's earnings last quarter?

Royalty Pharma plc (NASDAQ:RPRX) announced its quarterly earnings results on Wednesday, November, 10th. The biopharmaceutical company reported $0.17 earnings per share for the quarter, missing the consensus estimate of $0.69 by $0.52. The biopharmaceutical company had revenue of $587 million for the quarter, compared to the consensus estimate of $568.92 million. Royalty Pharma had a trailing twelve-month return on equity of 28.30% and a net margin of 14.12%. During the same quarter in the prior year, the company earned $0.48 EPS.

How often does Royalty Pharma pay dividends? What is the dividend yield for Royalty Pharma?

Royalty Pharma announced a quarterly dividend on Monday, April 17th. Shareholders of record on Friday, May 19th will be given a dividend of $0.20 per share on Thursday, June 15th. This represents a $0.80 annualized dividend and a dividend yield of 2.43%. The ex-dividend date is Thursday, May 18th.
Read our dividend analysis for RPRX
.

Is Royalty Pharma a good dividend stock?

Royalty Pharma (NASDAQ:RPRX) pays an annual dividend of $0.80 per share and currently has a dividend yield of 2.32%. The company has been increasing its dividend for 3 consecutive year(s), indicating that it does not yet have a strong track record of dividend growth. The dividend payout ratio is 145.45%. Payout ratios above 75% are not desirable because they may not be sustainable. Based on earnings estimates, RPRX will have a dividend payout ratio of 20.36% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for RPRX.

What other stocks do shareholders of Royalty Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Royalty Pharma investors own include Twitter (TWTR), Bausch Health Companies (BHC), NVIDIA (NVDA), (RLYP) (RLYP), Aeterna Zentaris (AEZS), Advanced Micro Devices (AMD), Netflix (NFLX), QUALCOMM (QCOM), Salesforce (CRM) and Twilio (TWLO).

When did Royalty Pharma IPO?

(RPRX) raised $1.9 billion in an initial public offering on Tuesday, June 16th 2020. The company issued 70,000,000 shares at a price of $25.00-$28.00 per share. J.P. Morgan, Morgan Stanley, BofA Securities, Goldman Sachs, Citigroup and UBS Investment Bank acted as the underwriters for the IPO and Evercore ISI, Cowen and SunTrust Robinson Humphrey were co-managers.

What is Royalty Pharma's stock symbol?

Royalty Pharma trades on the NASDAQ under the ticker symbol "RPRX."

Who are Royalty Pharma's major shareholders?

Royalty Pharma's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include FMR LLC (6.58%), BlackRock Inc. (3.27%), Baillie Gifford & Co. (3.12%), JPMorgan Chase & Co. (1.43%), State Street Corp (1.37%) and Geode Capital Management LLC (0.99%). Insiders that own company stock include 1978 Sicaf Sif SA - Gg St Gg, 1978 Sicaf Sif SA Gg, Adage Capital Partners Gp, LL, George W Lloyd, Henry A Fernandez, James F Reddoch, James F Reddoch, Mario Germano Giuliani, Marshall Urist, Pablo G Legorreta, Rory B Riggs, Sanjay Kumar Singh, Scientific Corp Boston, Terrance P Coyne and William E Ford.
View institutional ownership trends
.

How do I buy shares of Royalty Pharma?

Shares of RPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Royalty Pharma's stock price today?

One share of RPRX stock can currently be purchased for approximately $32.91.

How much money does Royalty Pharma make?

Royalty Pharma (NASDAQ:RPRX) has a market capitalization of $19.98 billion and generates $2.24 billion in revenue each year. The biopharmaceutical company earns $42.83 million in net income (profit) each year or $0.55 on an earnings per share basis.

How can I contact Royalty Pharma?

Royalty Pharma's mailing address is 110 E 59th Street, New York NY, 10022. The official website for the company is www.royaltypharma.com. The biopharmaceutical company can be reached via phone at 212-883-0200 or via email at ir@royaltypharma.com.

This page (NASDAQ:RPRX) was last updated on 6/10/2023 by MarketBeat.com Staff

My Account -